Instil Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Instil Bio, Inc. (TIL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 562.01 thousand shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-03-27
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-12-31 was 808.45K shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-09-30 was 334.35K shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-06-30 was 1.79M shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2021-03-31 was 6.48M shares.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 562.01K shares, a 2.78% increase from fiscal 2024.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 546.80K shares, a 101.09% increase from fiscal 2023.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 271.92K shares, a 9.57% decline from fiscal 2022.
- Instil Bio, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 300.71K shares, a 96.81% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 562.01K shares 10-K · filed 2026-03-27 | ||||
| 2024-12-31 | 546.80K shares 10-K · filed 2026-03-27 | ||||
| 2023-12-31 | 271.92K shares 10-K · filed 2025-03-04 | ||||
| 2022-12-31 | 300.71K shares 10-K · filed 2024-03-21 | 6.02M shares 10-K · filed 2023-03-31 | |||
| 2021-12-31 | 808.45K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | 1.14M shares derived: sum of 2 quarters · filed 2023-03-31 | 2.94M shares derived: sum of 3 quarters · filed 2023-03-31 | 9.41M shares 10-K · filed 2023-03-31 | |
| 2021-09-30 | 334.35K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | 2.13M shares derived: sum of 2 quarters · filed 2021-11-15 | 8.60M shares 10-Q · filed 2021-11-15 | ||
| 2021-06-30 | 1.79M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 8.27M shares 10-Q · filed 2021-08-12 | |||
| 2021-03-31 | 6.48M shares 10-Q · filed 2021-05-13 | ||||
| 2020-12-31 | 10.74M shares 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |